A5017716856- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Radiomics and Machine Learning in Medical Imaging
- Ferroptosis and cancer prognosis
- Brain Metastases and Treatment
- Glioma Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Advanced X-ray and CT Imaging
- Medical Imaging and Analysis
- MRI in cancer diagnosis
- Radiation Therapy and Dosimetry
- Cancer Research and Treatments
- Cancer Diagnosis and Treatment
- Immune cells in cancer
- Medical Imaging Techniques and Applications
- Immunotherapy and Immune Responses
- Radiation Dose and Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Lipids, and Metabolism
- Breast Cancer Treatment Studies
The University of Texas Southwestern Medical Center
2016-2025
Southwestern Medical Center
2016-2025
Harold C. Simmons Comprehensive Cancer Center
2014-2023
Radiation Oncology Associates
2018-2021
Simmons University
2015
Albert Einstein College of Medicine
2008-2013
Montefiore Medical Center
2007-2013
SUNY Downstate Health Sciences University
2006
Programmed death–ligand 1 (PD-L1) expression on tumor cells is essential for T cell impairment, and PD-L1 blockade therapy has shown unprecedented durable responses in several clinical studies. Although higher of associated with a better immune response after Ab blockade, some PD-L1–negative patients also respond to this therapy. In the current study, we explored whether or host was anti–PD-L1–mediated 2 different murine models. Using real-time imaging whole tissues, found that anti–PD-L1...
Cell membrane-derived nanoparticles (NPs) have recently gained popularity due to their desirable features in drug delivery such as mimicking properties of native cells, impeding systemic clearance, and altering foreign body responses. Besides NP technology, adoptive immunotherapy has emerged its promise cancer specificity therapeutic efficacy. In this research, we developed a biomimetic carrier based on chimeric antigen receptor (CAR) transduced T-cell membranes. For that purpose, anti-HER2...
Significance The role of tumor-associated neutrophils (TANs) in cancer progression versus regression remains controversial. TANs are known to have dichotomous antitumor (N1) and protumor (N2) phenotypes depending on the tumor microenvironment. Past studies demonstrated that polarized from an N2 N1 phenotype absence TGF-β; not induced IFN-β. Our study demonstrates radiation therapy (RT) and, especially, combination RT granulocyte colony-stimulating factor (G-CSF) induces polarization...
By leveraging tumorgraft (patient-derived xenograft) RNA-sequencing data, we developed an empirical approach, DisHet, to dissect the tumor microenvironment (eTME). We found that 65% of previously defined immune signature genes are not abundantly expressed in renal cell carcinoma (RCC) and identified 610 novel immune/stromal transcripts. Using eTME, genomics, pathology, medical record data involving >1,000 patients, established inflamed pan-RCC subtype (IS) enriched for regulatory T cells,...
Radiotherapy (RT) plus long-term androgen suppression (AS) are a standard treatment option for patients with high-risk localized prostate cancer. We hypothesized that docetaxel chemotherapy (CT) could improve overall survival (OS) and clinical outcomes among
Accurate segmentation of prostate and surrounding organs at risk is important for cancer radiotherapy treatment planning. We present a fully automated workflow male pelvic CT image using deep learning. The architecture consists 2D organ volume localization network followed by 3D volumetric prostate, bladder, rectum, femoral heads. used multi-channel U-Net with encoding arm modified aggregated residual networks, known as ResNeXt. models were trained tested on dataset comprising 136 patients....
Inter-and intra-observer variation in delineating regions of interest (ROIs) occurs because differences expertise level and preferences the radiation oncologists. We evaluated accuracy a segmentation model using U-Net structure to delineate prostate, bladder, rectum male pelvic CT images. The dataset used for training testing consisted raw scan images 85 prostate cancer patients. designed 2D directly learn mapping function that converts grayscale image its corresponding OAR segmented image....
LBA5002 Background: High-risk, localized prostate cancer (PCa) patients have a relatively poor prognosis. We hypothesized that the addition of adjuvant docetaxel and prednisone to long-term (24 month) AS radiation therapy (RT) would improve overall survival (OS). Methods: RTOG 0521 opened December 2005 closed August 2009 with targeted accrual 600 cases. It was designed detect improvement in 4-year OS from 86% 93% 51% hazard reduction (HR = 0.49). Under 0.05 1-sided type I error 90% power, at...
614 Background: Dual ICI with nivolumab/ipilimumab (N/I) has become a standard of care (SOC) for patients (pts) mRCC. Since the failure to respond may be due lack immune recognition, novel vaccination approaches and stimulation innate system (e.g. stimulator interferon genes (STING) agonists) are being pursued in clinical trials. Because preclinical studies using SBRT have demonstrated a.) release tumor antigens, b.) STING pathway activation c.) synergy ICI, we conducted study explore safety...
Renal cell carcinoma is refractory to conventional radiation therapy but responds higher doses per fraction. However, the dosimetric data and clinical factors affecting local control (LC) are largely unknown. We aimed evaluate safety efficacy of stereotactic ablative (SAbR) for extracranial renal metastases.We reviewed 175 metastatic lesions from 84 patients treated with SAbR between 2005 2015. LC toxicity after were assessed Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1...
There is significant interest in the use of stereotactic ablative radiotherapy (SABR) as a treatment modality for liver metastases. A variety SABR fractionation schemes are clinical use. We conducted phase I dose-escalation study to determine maximum tolerated dose single-fraction SABR. Patients with metastases from solid tumors, whom critical volume constraint could be met, were treated Seven patients enrolled first group, prescription 35 Gy. Dose was then escalated 40 Gy single fraction,...
<h3>Background</h3> Programmed death-ligand 1 (PD-L1) expression in metastatic renal cell carcinoma (RCC) correlates with a worse prognosis, but whether it also predicts responsiveness to anti-PD-1/PD-L1 therapy remains unclear. Most studies of PD-L1 are limited by evaluation primary rather than sites, and biopsy samples, which may not be representative. These limitations overcome immuno–positron emission tomography (iPET), an emerging tool allowing the detection surface proteins...